Nicholas Maestas's most recent trade in Tempest Therapeutics Inc was a trade of 200,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tempest Therapeutics Inc | Nicholas Maestas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | VP of Strategy and Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | VP of Strategy and Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 38,425 | 38,425 | - | - | Employee Stock Option (right to buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | VP of Strategy and Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 51,270 | 51,270 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | VP of Strategy and Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 19,500 | 19,500 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | VP of Strategy and Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 23,225 | 23,225 | - | - | Stock Option (Right to Buy) |